Cardiomyocyte and vascular smooth muscle independent 11\(\beta\)-hydroxysteroid dehydrogenase 1 amplifies infarct expansion, hypertrophy and the development of heart failure following myocardial infarction in male mice

Christopher I White\(^1\), Maurits A Jansen\(^1,2\), Kieran McGregor\(^1\), Katie J Mylonas\(^1\), Rachel V Richardson\(^1\), Adrian Thomson\(^2\), Carmel M Moran\(^1,2\), Jonathan R Seckl \(^1\), Brian R Walker \(^1\), Karen E Chapman\(^1\) & Gillian A Gray\(^1\)*

\(^1\)BHF/University Centre for Cardiovascular Science, University of Edinburgh, Queens Medical Research Institute, 47 Little France Cres, Edinburgh EH16 4TJ, Scotland, UK.; \(^2\)Edinburgh Preclinical Imaging, University of Edinburgh, College of Medicine & Veterinary Medicine, 47 Little France Cres, Edinburgh EH16 4TJ, Scotland, UK.

Global deficiency of 11\(\beta\)-hydroxysteroid dehydrogenase 1 (11\(\beta\)-HSD1), an enzyme that regenerates glucocorticoids within cells, promotes angiogenesis and reduces acute infarct expansion following myocardial infarction (MI) suggesting that 11\(\beta\)-HSD1 activity has an adverse influence on wound healing in the heart after MI. The present study investigated whether 11\(\beta\)-HSD1 deficiency could prevent the development of heart failure following MI, and examined whether 11\(\beta\)-HSD1 deficiency in cardiomyocytes and vascular smooth muscle cells confers this protection. Male mice with global deficiency in 11\(\beta\)-HSD1, or with \(Hsd11b1\) disruption in cardiac and vascular smooth muscle (via \(SM22\alpha-Cre\) recombinase) underwent coronary artery ligation for induction of MI. Acute injury was equivalent in all groups. However, by 8 weeks after induction of MI, relative to C57Bl/6 wild type, globally 11\(\beta\)-HSD1 deficient mice had reduced infarct size (34.7±2.1%LV vs 44.0±3.3%LV, \(P=0.02\)), improved function (ejection fraction 33.5±2.5% vs 24.7±2.5%, \(P=0.03\)) and reduced ventricular dilation (LVEDV 0.17±0.01ml vs 0.21±0.01ml, \(P=0.01\)). This was accompanied by a reduction in hypertrophy, pulmonary edema and in the expression of genes encoding atrial natriuretic peptide and \(\beta\)-myosin heavy chain. None of these outcomes, nor promotion of peri-infarct angiogenesis during infarct repair, were recapitulated when 11\(\beta\)-HSD1 deficiency was restricted to cardiac and vascular smooth muscle. 11\(\beta\)-HSD1 expressed in cells other than cardiomyocytes or vascular smooth muscle limits angiogenesis and promotes infarct expansion with adverse ventricular remodeling after MI. Early pharmacological inhibition of 11\(\beta\)-HSD1 may offer a new therapeutic approach to prevent heart failure associated with ischemic heart disease.

Interventions to restore perfusion following myocardial infarction (MI) have significantly enhanced acute survival (1). However, many patients survive with injury to their myocardium that is replaced during wound healing by noncontractile scar tissue. In the longer term structural, functional and metabolic remodeling of the remaining ventricle to compensate for contractile deficiency and alteration in wall stress promotes progression to heart failure (2). Retention of functional cardiomyocytes is critical in limiting subsequent adverse ventricular remodeling. In
Experimental models cardiomycocyte loss can be reduced by intervention at the time of reperfusion, but successful translation of these interventions to the clinic has been limited (3, 4). Cardiomyocyte death also occurs in the peri-infarct area during infarct healing and scar formation, leading to infarct expansion. Promotion of angiogenesis during this phase can limit infarct expansion and subsequent adverse remodeling (5–9).

Glucocorticoids (physiological cortisol and corticosterone, as well as synthetic forms) are known to suppress angiogenesis (10). Plasma levels of cortisol increase in the hours after MI following activation of the hypothalamic-pituitary-adrenal axis and may protect cardiomyocytes from acute ischemic injury (11–13), but as circulating levels are reduced within days of MI, they are unlikely to impact on the later angiogenesis that is associated with infarct healing. However, active glucocorticoids can also be regenerated locally from circulating inert 11-keto metabolites by the enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), that is expressed in many cells, including in cardiomyocytes, fibroblasts, and smooth muscle cells in the heart (14). Genetic disruption of Hsd11b1, the gene encoding 11β-HSD1 does not change initial ischemic injury in the murine heart following experimental MI, but leads to enhancement of peri-infarct vessel density (8, 10). Importantly, vessels formed during infarct healing mature to maintain blood flow to the peri-infarct area in 11β-HSD1 deficient mice and increased vessel density is associated with shorter and thicker infarcts and with retention of cardiac function (8). Pharmacological inhibitors of 11β-HSD1 have reached phase 2 clinical development for use in diabetes and cognitive dysfunction and have potential as a new therapeutic approach for promotion of angiogenesis, including post-MI (15, 16). However, whether 11β-HSD1 deficiency can prevent maladaptive ventricular remodeling and progression to heart failure following MI has not been examined.

11β-HSD1 activity is not detectable in endothelial cells, but the enzyme is present in the vessel wall where expression and activity is associated with smooth muscle cells (17, 18). Whether glucocorticoids regenerated by 11β-HSD1 in vascular smooth muscle cells act as an endogenous brake upon angiogenesis in the healing infarct, or indeed upon any aspect of ventricular remodeling after MI, is unknown. A recent study has shown that myocardial expression of 11β-HSD1 is increased in an MI-independent model of pathological hypertrophy and that ventricular remodeling can be reversed by pharmacological inhibition of 11β-HSD1 without any change in vessel density (19). This suggests that 11β-HSD1 has effects in the heart over and above those involving angiogenesis, potentially via 11β-HSD1 expressed in cardiomyocytes.

The present study tested the hypothesis that long term maladaptive structural and functional myocardial remodeling and the development of heart failure following MI are attenuated by 11β-HSD1 deficiency. To establish the contribution of 11β-HSD1 specifically in vascular smooth muscle cells and cardiomyocytes to the beneficial outcome following MI seen in mice lacking the enzyme globally, targeted deletion of 11β-HSD1 in these cell types was investigated.

Materials and Methods

Experimental Animals. All experiments involving animals were approved by the University of Edinburgh Animal Welfare and Ethical Review Body and by the UK Home Office. Experiments used adult male (10–14 weeks of age) mice with global deficiency on a C57Bl6 genetic background (Hsd11b1<sup>−/−</sup>) (8, 20), with C57Bl6/6 controls, or mice in which deletion was targeted to vascular smooth muscle and cardiomyocytes (21, 22). These Hsd11b1<sup>−/−</sup>Sm22α-Cre<sup>+</sup> (Hsd11b1<sup>CVCre</sup><sup>+</sup>) were generated by crossing Sm22α-Cre mice with Hsd11b1<sup>−/−</sup> mice, homozygous for a “floxed” allele of Hsd11b1 (generated by Artemis Pharmaceuticals, Cologne, Germany, directly onto a C57Bl6/J background). LoxP sites were placed flanking exon 3 of the mouse Hsd11b1 gene, excision of which results in a “null allele” by “out of frame splicing” from exon 2 to exon. Controls were Hsd11b1<sup>flo/flo</sup> (Cre<sup>−</sup>) littermates (Hsd11b1<sup>CVCre</sup><sup>−</sup>). Following Cre genotyping, appropriate targeting was confirmed by determination of Hsd11b1 RNA and 11β-HSD1 protein content in myocardium, aorta, liver and skeletal muscle.

Induction of MI. Myocardial infarction (MI) was induced by coronary artery ligation (CAL, as previously described (8, 23)) in Hsd11b1<sup>−/−</sup> mice, in age matched C57Bl6 mice (WT), in Hsd11b1<sup>CVCre</sup> and in Hsd11b1<sup>CVCre</sup> mice. Briefly, following injection of analgesic (buprenorphine, 0.05 mg/kg, s.c.) and intubation for mechanical ventilation (120 strokes/min, 200 μl stroke volume, HSE-Harvard MiniVent), the chest was opened at the fourth intercostal space and the pericardium was removed to allow ligation of the left anterior descending coronary artery (LAD) (6–0 Prolene suture, Ethicon). Successful ligation was confirmed by blanching of the left ventricle (LV), and the chest was closed using a 5–0 Mersilk suture (Ethicon), ensuring that no air remained in the chest cavity. The skin was closed using 9 mm stainless steel autoclips (Harvard Apparatus). Following surgery 1.5 ml sterile saline (0.9%, s.c.) was administered to aid recovery. 24h after induction of MI, a blood sample (45 μl) was collected from the tail vein into a tube containing sodium citrate buffer for assay of troponin I by ELISA (Life Diagnostics High Sensitivity Mouse Cardiac Troponin-I ELISA Kit) to assess the extent of injury (24).

Structural & Functional Characterization. 8 weeks after coronary artery ligation surgery, cardiac structure, function and infarct size was measured using magnetic resonance imaging (MRI), as previously described (25). Temperature was maintained at 37°C, respiration rate at 50–60 breaths per minute and...
heart rate at 500–550 bpm during imaging in isoflurane (1.3–1.8%) anesthetized mice. Animals were placed in a supine position inside a 7T MRI scanner (Agilent Technologies) with a 39 mm quadrature radiofrequency coil. Short axis cardiac images were acquired using an ECG-triggered and respiratory gated gradient echo ‘cine’ sequence (TR/TE = 7.3/2.7 ms with a flip angle of 15°) with gradient and RF spoiling. Nine consecutive 1 mm thick slices from 12–13 time frames were acquired, which encompassed the entire heart from base to apex. The field of view was 30 mm with a 192 × 192 matrix and 4 averages were used. ImageJ software (National Institutes of Health) was used to assess left ventricular (LV) end diastolic volume, LV end systolic volume, and ejection fraction. Infarct size was measured by segmenting each short axis image into 20 sections. Any section which was thinned and akinetic or dyskinetic over the cardiac cycle was designated as infarcted tissue. Gray scale contrast also which was thinned and akinetic or dyskinetic over the cardiac cycle was designated as infarcted tissue. Gray scale contrast also

Western Blotting. 11β-HSD1 protein content was assessed by Western blot as previously described (26), in the heart, liver, aorta and skeletal muscle to confirm appropriate deletion in Hsd11b1Cre mice. Briefly 50 mg of tissue was homogenized in 300 μl lysis buffer (RIPA buffer (Sigma), protease & phosphatase inhibitor cocktails (Sigma) then centrifuged at 12 000 G for 15 minutes at 4°C. Proteins were separated by SDS-PAGE then transferred (Trans-Blot Semi Dry Transfer Cell, Bio-Rad) to a nitrocellulose membrane. After blocking (milk powder in TBS buffer with Tween 20) the membrane was incubated overnight at 4°C with primary 11β-HSD1 antibody (1/10000 in 5% BSA, generated in house in sheep (26)). The membrane was washed before application of horse radish peroxidase (HRP) conjugated donkey-antisheep secondary antibody (1/5000, Abcam, ab97125) then washed again and exposed to antimouse β-actin (1/10000, Cell Signaling Technologies) as a loading control, to HRP conjugated rabbit antisheep secondary antibody (Abcam, ab6728) then developed (ECL Prime Western Blotting Detection Reagent (GE Healthcare) and exposed to X-ray film for detection. 11β-HSD1 protein levels was calculated by normalizing the density of this band to that of β-actin protein.

Histological and Immunohistochemical Analysis. Infarct area and thickness were assessed in Mason’s Trichrome stained paraffin sections. The infarcted area was selected manually and expressed as a percentage of the total area of the LV (Image Pro 6.2 and a Stereologer Analyzer 6 (MediaCybernetics)). Infarct thickness was determined by averaging scar thickness from five equally-spaced points along the length of the infarct. For macrophages, slides were incubated overnight with biotinylated rat antimonue Mac 2 (1/6000, Cedarlane), or for alternatively activated macrophages with rabbit antimonue Ym1 (1/500, Stem Cell Technologies) followed by a biotinylated goat antirabbit (Vector). Color was developed with a few drops of diaminobenzidine (DAB, Vector) according to the manufacturers instructions. A color threshold was set manually so as to only select positive brown staining for Mac2 and the area of this positive staining within the infarct was calculated automatically. Total macrophage infiltration was then expressed as the percentage area of positive brown DAB staining within the infarct. Peri-infarct angiogenesis was assessed in tissue sections by detection of immunoreactive CD31 (rabbit antimonue CD31 (1/50, Abcam,) in PBS) with a biotinylated goat antirabbit (Vector) secondary antibody. DAB solution was added to each section for visualization. Angiogenesis was assessed in 20 randomly assigned fields of view around the infarct border. The number of CD31 + vessels were measured and categorised according to size; capillaries (<4 μm diameter), small arterioles (4–200 μm diameter) and large arterioles (>200 μm diameter).

Cardiomyocyte cross-sectional area was assessed in isoelectric B4 (Alexa Fluor conjugated isoelectric B4 (1/100, Thermo Fisher) and wheat germ agglutinin (wheat germ agglutinin-rhodamine (1/75, Vector) stained paraffin sections as previously described (27). Five randomly selected regions of interest were visualized in the LV free wall. Adobe Photoshop CS5 Extended (Adobe) was
used to calculate cross-sectional area in cardiomyocytes which appeared to be cut in the short axis as judged by (a) a nucleus in the middle of the cell and, (b) surrounded by capillaries which were also cut in the short axis.

**Statistical analysis.** Prism 6 f for Mac OS X (GraphPad Software Inc) was used for 2 way ANOVA (7 day Hsd11b1CVCre+ and Hsd11b1CVCre− sham and MI) or two-tailed unpaired Student’s t tests (comparisons of Hsd11b1−/− and WT, or Hsd11b1CVCre+ and Hsd11b1CVCre−). All values are expressed as mean ± SEM, statistical significance was accepted at P < .05.

**Results**

Global but not cardiomyocyte and vascular smooth muscle cell disruption of Hsd11b1 prevents infarct thinning and expansion during the development of heart failure

Hsd11b1 mRNA and 11β-HSD1 protein levels were both significantly reduced in the myocardium and aorta, but not in liver or skeletal muscle, of Hsd11b1CVCre+ mice relative to their littermate controls (Hsd11b1CVCre−), consistent with selective disruption of gene expression in cardiomyocytes and vascular smooth muscle directed by SM22-α-Cre (Figure 1) (21). Blood pressure, contractile function and heart weight:body weight ratio were not significantly different to wild type mice (Supplemental Figure 1). Troponin I in plasma collected from the tail vein 24 h after coronary artery ligation, a measure of ischemic injury, increased to over 40 ng/ml in all groups (Supplemental Figure 2), confirming that the extent of the initiating myocardial injury is not influenced by 11β-HSD1 deficiency (8). In contrast, when injury was assessed at 8 weeks after MI (Figure 2), either in vivo by MRI or in histological sections, infarct area was significantly less (P < .05) and this was confirmed by postmortem gravimetric analysis (Figure 4a, P < .001). Reduced hypertrophic remodeling in hearts from Hsd11b1−/− mice was evidenced by a significant decrease in cardiomyocyte cross sectional area (Figure 4b, P < .05) and in the expression of the fetal cardiomyocyte markers α-MHC (relative to β-MHC, P < .05) and ANP (P < .01, Figure 4c), compared to their WT controls. Expression of the profibrotic genes TGFβ1, and the Col1a2 and Col3a1 genes encoding the major collagen, was unaffected by global or cardiovascular specific deficiency of 11β-HSD1 (Figure 5).

**Peri-infarct angiogenesis and infarct expansion at 7 days after induction of MI are not influenced by cardiomyocyte and vascular smooth muscle selective depletion of Hsd11b1**

As long term outcomes following MI were not improved when Hsd11b1 disruption was restricted to cardiomyocytes and vascular smooth muscle, a further study was conducted to investigate early wound healing and infarct expansion in these mice. By 7 days after induction of MI, during infarct repair, high resolution ultrasound showed that the extent of LV dilation and loss of function was similarly impaired in all mice relative to sham-operated mice (Figure 6a). Cardiomyocyte and vascular smooth muscle restricted deletion of Hsd11b1 also failed to influence infarct size (Figure 6b) or the extent of peri-infarct angiogenesis during infarct healing (Figure 6c). Macrophage recruitment was increased post-MI relative to sham operation (Figure 6d), but neither recruitment nor polarization of macrophages towards a YM-1 positive ‘M2’ macrophage phenotype was influenced in hearts from Hsd11b1CVCre+ compared to Hsd11b1CVCre− mice (Figure 6d).

**Discussion**

In this study we present three important findings: (1) that 11βHSD1 amplifies infarct expansion and progression to...
heart failure after MI, supporting the use of pharmacological inhibitors of 11βHSD1 to prevent the development of heart failure in this setting; (2) that disruption of the Hsd11b1 gene in cardiac muscle does not prevent the expression of fetal genes or hypertrophic remodeling after MI suggesting that 11βHSD1 in cardiomyocytes does not play a direct role in regulating this process; (3) that the promotion of peri-infarct angiogenesis associated with prevention of early infarct expansion in mice with global 11βHSD1 deficiency (8) does not involve 11βHSD1 in smooth muscle cells of the vessel wall.

Following MI, ventricular remodeling and heart failure develop in response to loss of contractile myocardial tissue that is not replaced after injury. The extent of this early injury is a key determinant of long-term outcome (28). In the present study, initial myocardial ischemic injury, as assessed by plasma levels of cardiac troponin I, was not influenced by 11β-HSD1 deficiency, confirming our previous observations where infarct injury was assessed directly early after MI (8). Glucocorticoids can protect the heart from ischemic injury, and systemic glucocorticoid, increased as a result of HPA activation in response to MI,

![Figure 1](Confirmation of cardiovascular specific 11β-HSD1 deletion. Hsd11b1 mRNA and 11β-HSD1 protein were assessed by rt-PCR (normalized to β-actin housekeeping gene) and Western blotting (normalized to β-actin loading control) respectively in heart, aorta, liver and skeletal muscle from Hsd11b1<sup>fl/flSm22<sup>-Cre<sup>−</sup> (Hsd11b1<sup>CVCRe</sup>) and control Hsd11b1<sup>fl/flSm22<sup>-Cre<sup>−</sup> (Hsd11b1<sup>CVCRe</sup>) mice. Expression in hsd11b1<sup>CVCRe</sup> is expressed relative to maximum achieved in tissue from Hsd11b1<sup>CVCRe</sup>− *** P < .001, ** = P < .01 vs parallel control; n = 4/ group.)
is dominant in the first 24h after MI. We have already shown that this early peak in plasma glucocorticoid concentration after MI is not altered in 11β-HSD1 deficient mice, therefore it is not surprising that early injury is also unaffected in these mice (8). However by 8 weeks after induction of injury the infarct had expanded and thinned to a lesser degree in mice with global deficiency of 11β-HSD1, and this was associated with less ventricular dilatation, a key prognostic indicator of outcome in human heart failure (2, 29). Decreased dilatation in the present study was accompanied by diminished expression of ANP, consistent with lowered wall stress (30), as well as reduction of ventricular dysfunction and pulmonary edema, together indicating prevention of progression to heart failure. This outcome is consistent with a detrimental influence of 11β-HSD1 on wound healing and remodeling that occur in response to injury.

Replacement of damaged myocardium by noncontractile scar tissue induces cardiomyocytes in the noninfarcted ventricle to undergo hypertrophic remodelling to maintain cardiac output, resulting in an increase in myocardial mass. Here, heart mass, assessed either in vivo by MRI, or ex vivo gravimetrically, was reduced in mice with global deficiency in 11β-HSD1. As well as increased cross-sectional area, cardiomyocytes undergoing pathological hypertrophy show re-expression of fetal genes, including those encoding ANP and β myosin heavy chain (βMHC). Increased expression of βMHC relative to the adult aMHC isoform is associated with loss of cardiomyocyte contractility in murine models (31). In the present study it is clear that global deficiency in 11β-HSD1 suppresses hypertrophic remodeling and reduces re-expression of fetal genes consistent with retention of function and reduction of wall stress. Recent data have linked a common variation in the Hsd11b1 gene to LV mass in man (32). Reversal of pathological hypertrophy by pharmacological inhibition of 11β-HSD1 in an MI-independent murine model also supports a specific role for 11β-HSD1 in the regulation of cardiomyocyte hypertrophy (19). However, neither modification of fetal genes, nor changes in myocyte cross sectional area were observed when Hsd11b1 deletion was limited to cardiomyocytes and vascular smooth muscle. This is consistent with a mechanism that is dependent on prohypertrophic signaling from other cells in the heart that express 11β-HSD1. Indeed, residual expression of Hsd11b1, evident in RNA and protein analysis of hearts from Hsd11b1Cre<sup>++</sup> mice, supports sites of expression in the heart over and above cardiomyocytes and vascular smooth muscle. Transcriptomic analysis has revealed that Hsd11b1 is enriched 6-fold in cardiac fibro-

![Figure 2. Global, but not cardiovascular specific, 11β-HSD1 deficiency reduces infarct expansion post-MI. Infarct injury was compared in wild type (WT) and global 11β-HSD1 deficient mice (Hsd11b1<sup>−/−</sup>), and in mice with cardiomyocyte and vascular smooth muscle specific deletion (Hsd11b1<sup>CVCre<sup>−</sup></sup>) and respective control (Hsd11b1<sup>CVCre<sup>+</sup></sup>) at 8 weeks after induction of MI by (top panel) MRI and by (lower panels) histology (Masson’s trichrome, MT) to determine infarct area and infarct thickness. Paired groups were compared by Student’s t test *P < .05, **P < .01, ***P < .005; n = 6–8/group.](attachment:image.png)
blasts relative to fibroblasts from other sources (33). Fibroblasts release a number of immunomodulatory and hypertrophy regulating factors and could be a key site for local regulation of cardiomyocyte growth during remodeling (34, 35). 11β-HSD1 has previously been shown to regulate the release of inflammatory mediators in synovial fibroblasts (36, 37), and this mechanism merits further investigation in the heart. Resident or recruited myeloid cells also express Hsd11b1 and can regulate cardiomyocyte hypertrophy (38, 39). Alternatively, if infarct size is the primary driver for adaptive hypertrophy following MI (28), then reduction of infarct expansion in mice with global 11β-HSD1 deficiency may be sufficient to diminish changes in cardiomyocyte gene expression and size. It is feasible that loss of 11β-HSD1 in other organs e.g., the kidney have indirect effects on hemodynamic stress during the development of heart failure.

We have previously demonstrated that peri-infarct angiogenesis during infarct healing is enhanced in globally 11β-HSD1 deficient mice (8, 10) and that this is associated with development of shorter and thicker infarcts (8). Hsd11b1 is expressed in the smooth muscle, but not the...
Figure 4. Hypertrophic remodeling and expression of fetal genes are inhibited in mice with global, but not cardiovascular, 11βHSD1 deficiency. Heart:body weight ratio (a) and cardiomyocyte cross-sectional area (b) were compared in mice global 11β-HSD1 deficient mice (Hsd11b1−/−) and wild-type (WT) controls, and in mice with cardiomyocyte and vascular smooth muscle specific deletion (Hsd11b1CVCre−) compared to respective floxed control (Hsd11b1CVCre−) at 8 weeks after induction of MI by coronary artery ligation. (c) Expression of fetal genes atrial natriuretic peptide (ANP (Nppa), upper panel) and α myosin heavy chain (αMHC (Myh6), expressed relative to βMHC (Myh7), lower panel) was determined by real-time PCR. * P < .05, ** P < .01, *** P < .005 vs matched control; n = 6–8/group.
endothelium, of murine vasculature (17), where it regulates inflammation and neointimal proliferation (40, 41). It has been suggested that 11β-HSD1 in the vessel wall may contribute to regulation of angiogenesis (10). However, in the present study targeted deletion of 11β-HSD1 in vascular smooth muscle failed to recapitulate enhancement of peri-infarct angiogenesis following MI. Enhancement of angiogenesis was previously linked to promotion of alternative macrophage activation during early infarct healing in globally Hsd11b1 deficient mice (8), this was also absent in mice with targeted deletion of Hsd11b1 in cardiomyocytes and vascular smooth muscle. Again, other cells present in the heart, including fibroblasts and myeloid cells, express 11β-HSD1 and can release molecules that regulate inflammation and angiogenesis (36–38), and these sites may be important for the effects of global 11β-HSD1 deficiency on infarct healing post-MI. Alternative macrophage activation can also promote fibrosis (42), potentially having a detrimental influence on cardiac function in the longer term. However, there was no evidence in the present study for an influence of 11β-HSD1 deficiency on the expression of a range of fibrosis associated genes in the failing LV.

The discussions above are focused around the principal that the primary function of 11β-HSD1 is to modulate intracellular availability of active glucocorticoid metabolites. Evidence is provided for appropriate reduction of gene expression and protein content in mice with targeted deletion of Hsd11b1, but a limitation of the study is the lack of direct evidence for reduction of active glucocorticoid regeneration through 11β-HSD1 activity in the targeted cells. While it is not therefore possible to state conclusively that reduced availability of locally generated glucocorticoids is key for the study outcomes, this limitation does not detract from the conclusion that 11β-HSD1 is a valid therapeutic target in the heart following MI.

A number of pharmacological inhibitors of 11β-HSD1 have been developed for the treatment of atherosclerotic disease.
and metabolic disease (15). We have found that 11β-HSD1 inhibitor can promote early angiogenesis and prevent infarct expansion when given immediately after MI (16), the present data suggests that pharmacological 11β-HSD1 inhibition also has the potential to reduce progression to heart failure. The use of mineralocorticoid receptor

### Table 1.

<table>
<thead>
<tr>
<th>Peptide/protein target</th>
<th>Antigen sequence (if known)</th>
<th>Name of Antibody</th>
<th>Manufacturer, catalog #, and/or name of individual providing the antibody</th>
<th>Species raised in; monoclonal or polyclonal</th>
<th>Dilution used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mac-2 (Galactosin)</td>
<td>Antimousehuman Mac-2</td>
<td>Cedarlane, CL0942AP</td>
<td>Rat, monoclonal</td>
<td>1 in 6000</td>
<td></td>
</tr>
<tr>
<td>Ym-1 (ECD-U)</td>
<td>Ym1- antibody</td>
<td>Stem Cell Technologies, 01-404</td>
<td>Rabbit, polyclonal</td>
<td>1 in 500</td>
<td></td>
</tr>
<tr>
<td>CD 31 (Pecam)</td>
<td>Anti-CD-31 antibody</td>
<td>Abcam, ab28384</td>
<td>Rabbit, polyclonal</td>
<td>1 in 50</td>
<td></td>
</tr>
<tr>
<td>Isletin B4</td>
<td>Isletin-SS-B4 from Griffonia simplicifolia</td>
<td>Thermo Fisher, 121413</td>
<td>Rabbit, polyclonal</td>
<td>1 in 100</td>
<td></td>
</tr>
<tr>
<td>a-actinin</td>
<td>a-actinin antibody</td>
<td>Vector Laboratories RL-7022</td>
<td>Rabbit, polyclonal</td>
<td>1 in 75</td>
<td></td>
</tr>
<tr>
<td>11β-HSD1</td>
<td>11β-HSD1 antibody</td>
<td>Prof Karen Chapman</td>
<td>Sheep</td>
<td>1 in 1000</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6. Cardiovascular selective deletion of 11βHSD1 does not modify early infarct healing Structural and functional remodelling (a), infarct size (b), peri-infarct angiogenesis (c), macrophage density and polarization (e), were all comparable in Hsd11b1CVCre+ and control floxed mice (Hsd11b1CVCre−) mice during infarct healing 7 days after induction of MI. Left ventricular end diastolic area (LVEDA), LV end systolic area (LVESA), fractional shortening (FS) and EF (EF) were assessed by high resolution ultrasound in mice 7 days after induction of MI by coronary artery ligation, or sham operation (sham). Macrophages were identified by immunoreactivity for the secreted protein Mac-2 (d, upper panel) and alternatively activated macrophages by expression of immunoreactive Ym-1 (d, lower panel). ** P < .01, *** P < .005, vs sham of same genotype, n = 8/group.
(MR) antagonists in patients with heart failure is now well established (43). Recent clinical and experimental studies have highlighted additional benefits of MR antagonists when given early after MI, that include promotion of angiogenesis and prevention of infarct expansion (44, 45). Studies in mice with cardiomyocyte-restricted inactivation of the MR gene suggest that the clinical benefits of MR blocking therapy in MI and heart failure are mediated largely via cardiomyocyte-dependent mechanisms (46). As the present data show that the effects of Hsd11b1 gene targeting are cardiomyocyte independent, 11β-HSD1 inhibitors may offer additional benefits in patients already receiving MR antagonist therapy or an alternative in patients for whom hyperkalemia precludes the use of MR antagonists (47).

Acknowledgments

The authors acknowledge the technical assistance of Ross Lennen (MRL) and are grateful to Ms Tak-Yun Man for the generation and breeding of Hsd11b1<sup>Cvcr<sup>-/-</sup> mice.

Address all correspondence and requests for reprints to: *Dr Gillian A Gray, BHF/University Centre for Cardiovascular Science, The University of Edinburgh, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh, EH14 6TJ, Scotland, UK, tel: (44) 131 242 9213, email: gillian.gray@ed.ac.uk.*

Disclosure Summary: CIW, MAJ, KM, AT, RVR, CMM, KJM, KEC & GAG have nothing to declare. BRW and JRS are employees on relevant patents owned by the University of Edinburgh and licensed to Actinogen Medical, for whom BRW acts as a Consultant.

This work was supported by the Wellcome Trust (WT091720MA and WT083184). CIW was the recipient of a British Heart Foundation 4 year PhD studentship (FS/09/053). The Centre for Cardiovascular Science is supported by a British Heart Foundation Centre of Research Excellence Award.

References

1. Danchin N. Winning the battle against ST-segment-elevation myocardial infarction: continued progress, but still a long way to go. *Eur Heart J.* 2010;31:2580–2582.


